Back to Search
Start Over
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A gemcad study.
- Source :
- Investigational New Drugs; Dec2013, Vol. 31 Issue 6, p1573-1579, 7p
- Publication Year :
- 2013
-
Abstract
- Background Cisplatin and fluoropyrimidine (CF) are standard first- line treatment in advanced gastric cancer, but no second-line treatment has yet been established. We present a phase II study in which we evaluated the efficacy and toxicity of the combination of Sorafenib (S), and Oxaliplatin as second-line therapy. Methods Patients with progressive gastric adenocarcinoma after CF- first-line, ECOG 0-2, and measurable disease were included. The primary objective was PFS. Treatment doses were Oxaliplatin 130 mg/m/3 weeks and Sorafenib 800 mg/bid/d. Results We included 40 patients. CR was 2.5 % and SD was 47.2 %. Grade 3-4 toxic effects were neutropenia (9.8 %), thrombocytopenia (7.3 %), neurotoxicity (4.9 %) and diarrhea (4.9 %). Median PFS was 3 months (95 %CI: 2.3-4.1) and median OS was 6.5 months (95 % CI: 5.2-9.6). Time to progression (TTP) to first line therapy was a prognosis factor. Median OS was 9.7 months when time-to-progression during first-line chemotherapy was >6 months and 5.6 m when it was <6 months ( p = 0.04). Conclusions Time-to-progression under a CF-based first-line therapy determines subgroups of GC patients with different prognosis. The combination of Oxaliplatin-Sorafenib in advanced GC patients previously treated with CF appears safe, but our results do not support the implementation of a phase III trial. [ABSTRACT FROM AUTHOR]
- Subjects :
- ANTINEOPLASTIC agents
ACADEMIC medical centers
BLOOD testing
COMBINATION drug therapy
CLINICAL trials
DRUG side effects
MEDICAL cooperation
PHOSPHOTRANSFERASES
RESEARCH
RESEARCH funding
STOMACH tumors
SURVIVAL
OXALIPLATIN
PROPORTIONAL hazards models
DATA analysis software
DESCRIPTIVE statistics
KAPLAN-Meier estimator
CHEMICAL inhibitors
THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 01676997
- Volume :
- 31
- Issue :
- 6
- Database :
- Complementary Index
- Journal :
- Investigational New Drugs
- Publication Type :
- Academic Journal
- Accession number :
- 91843714
- Full Text :
- https://doi.org/10.1007/s10637-013-0020-2